文献速递临床试验与 GCP

利格列汀与格列美脲对2型糖尿病患者主要不良心血管结局的影响:CAROLINA随机临床试验

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

CAROLINA随机双盲活性对照非劣效试验纳入6042例相对早期2型糖尿病且心血管风险升高的成人,比较利格列汀5mg每日一次与格列美脲1-4mg每日一次。中位随访6.3年,主要复合心血管结局在利格列汀组356/3023例(11.8%)与格列美脲组362/3010例(12.0%)之间,HR 0.98(95.47%CI 0.84-1.14),满足非劣效但未达优效。

要点

  • 利格列汀组主要复合心血管结局11.8%,格列美脲组12.0%,HR 0.98(95.47%CI 0.84-1.14),非劣效成立。
  • 低血糖不良事件利格列汀组320例(10.6%)低于格列美脲组1132例(37.7%),HR 0.23(95%CI 0.21-0.26)。
  • 利格列汀组不良事件2822例(93.4%),格列美脲组2856例(94.9%);急性胰腺炎两组分别为15例(0.5%)与16例(0.5%)。

核心结论

  • 在相对早期2型糖尿病且心血管风险升高的成人中,与格列美脲相比,利格列汀中位6.3年治疗的心血管复合结局风险为非劣效。

研究设计与样本

  • 随机、双盲、活性对照、非劣效试验,2010年11月至2012年12月筛选,在43个国家607个医院和初级保健中心进行,纳入6042例参与者。
  • 纳入标准为成人2型糖尿病、糖化血红蛋白6.5%至8.5%且心血管风险升高;心血管风险升高定义为确诊动脉粥样硬化性心血管疾病、多重心血管危险因素、年龄至少70岁和微血管并发症证据。
  • 随访于2018年8月结束;6042例随机化参与者中6033例接受治疗和分析,平均年龄64.0岁,女性2414例(39.9%),平均糖化血红蛋白7.2%,糖尿病中位病程6.3年,42%有大血管疾病,59%曾接受二甲双胍单药治疗。
  • 干预为利格列汀5mg每日一次(n=3023)或格列美脲1至4mg每日一次(n=3010),在常规治疗基础上给药;研究者被鼓励根据临床需要强化降糖治疗,主要方式为加用或调整二甲双胍、α-葡萄糖苷酶抑制剂、噻唑烷二酮类或胰岛素。
  • 主要结局为心血管死亡、非致死性心肌梗死或非致死性卒中首次发生的时间,非劣效界值为利格列汀相对格列美脲风险比的双侧95.47%CI上限小于1.3。

主要发现

  • 主要结局发生在利格列汀组356/3023例(11.8%)与格列美脲组362/3010例(12.0%),HR 0.98(95.47%CI 0.84-1.14),非劣效P<.001,优效性P=.76。
  • 不良事件发生在利格列汀组2822例(93.4%)与格列美脲组2856例(94.9%)。
  • 经裁定确认的急性胰腺炎在利格列汀组15例(0.5%)与格列美脲组16例(0.5%)。
  • 至少1次低血糖不良事件发生在利格列汀组320例(10.6%)与格列美脲组1132例(37.7%),HR 0.23(95%CI 0.21-0.26)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not been tested against an active comparator. OBJECTIVE: This trial assessed cardiovascular outcomes of linagliptin vs glimepiride (sulfonylurea) in patients with relatively early type 2 diabetes and risk factors for or established atherosclerotic cardiovascular disease. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, active-controlled, noninferiority trial, with participant screening from November 2010 to December 2012, conducted at 607 hospital and primary care sites in 43 countries involving 6042 participants. Adults with type 2 diabetes, glycated hemoglobin of 6.5% to 8.5%, and elevated cardiovascular risk were eligible for inclusion. Elevated cardiovascular risk was defined as documented atherosclerotic cardiovascular disease, multiple cardiovascular risk factors, aged at least 70 years, and evidence of microvascular complications. Follow-up ended in August 2018. INTERVENTIONS: Patients were randomized to receive 5 mg of linagliptin once daily (n = 3023) or 1 to 4 mg of glimepiride once daily (n = 3010) in addition to usual care. Investigators were encouraged to intensify glycemic treatment, primarily by adding or adjusting metformin, α-glucosidase inhibitors, thiazolidinediones, or insulin, according to clinical need. MAIN OUTCOMES AND MEASURES: The primary outcome was time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke with the aim to establish noninferiority of linagliptin vs glimepiride, defined by the upper limit of the 2-sided 95.47% CI for the hazard ratio (HR) of linagliptin relative to glimepiride of less than 1.3. RESULTS: Of 6042 participants randomized, 6033 (mean age, 64.0 years; 2414 [39.9%] women; mean glycated hemoglobin, 7.2%; median duration of diabetes, 6.3 years; 42% with macrovascular disease; 59% had undergone metformin monotherapy) were treated and analyzed. The median duration of follow-up was 6.3 years. The primary outcome occurred in 356 of 3023 participants (11.8%) in the linagliptin group and 362 of 3010 (12.0%) in the glimepiride group (HR, 0.98 [95.47% CI, 0.84-1.14]; P < .001 for noninferiority), meeting the noninferiority criterion but not superiority (P = .76). Adverse events occurred in 2822 participants (93.4%) in the linagliptin group and 2856 (94.9%) in the glimepiride group, with 15 participants (0.5%) in the linagliptin group vs 16 (0.5%) in the glimepiride group with adjudicated-confirmed acute pancreatitis. At least 1 episode of hypoglycemic adverse events occurred in 320 (10.6%) participants in the linagliptin group and 1132 (37.7%) in the glimepiride group (HR, 0.23 [95% CI, 0.21-0.26]). CONCLUSIONS AND RELEVANCE: Among adults with relatively early type 2 diabetes and elevated cardiovascular risk, the use of linagliptin compared with glimepiride over a median 6.3 years resulted in a noninferior risk of a composite cardiovascular outcome. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01243424.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019. PMID: 31536101. doi:10.1001/jama.2019.13772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。